Lyme Disease

NEW YORK , April 1, 2024 /PRNewswire/ -- The Enzyme-Linked Immunosorbent Assay (ELISA) testing market is set for substantial expansion, with an estimated growth of USD 564.97 million between 2022 and 2027. This growth is attributed to various factors, including the increasing demand for frequent diagnostic testing among the aging population, the rise in toxicology testing in the food industry, and the surge in chronic diseases.To gain access to more vendor profiles available with Technavio, Download a PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2023-2027 Key Market Drivers: The surge in chronic diseases, such as cardiovascular diseases, cancer, chronic obstructive pulmonary disease, and type 2 diabetes, is a significant driver for the market. ELISA tests play a pivotal role not only in diagnosing these diseases but also in managing them effectively. These tests aid doctors in assessing disease severity, estimating prognosis, monitoring disease progression, and selecting appropriate therapies, thereby driving market growth. Trends Impacting Market Growth: Promotional activities are gaining prominence in the ELISA testing market, as companies seek to enhance product visibility and awareness. Strategies such as online resources, interactive videos, and workshops are being employed to educate both healthcare professionals and patients about the benefits of ELISA testing. This trend is expected to bolster market growth in the coming years. Challenges Faced: Stringent government regulations pose a challenge to market growth, particularly in terms of product commercialization. Meeting regulatory requirements, including clinical trials and approvals, can be time-consuming and costly for companies. Variations in regulations across different countries further compound these challenges, affecting product development and launch timelines.Get a glance of this market - Download a PDF Sample Report Major Market Players: Key companies driving the ELISA testing market include Abbott, Abcam plc, Agilent Technologies Inc., Amgen Inc., and others. These companies are implementing various strategies such as strategic alliances, partnerships, and product launches to strengthen their market presence. Market Segmentation: The vaccine development segment is expected to witness significant growth during the forecast period. ELISA testing plays a crucial role in assessing immune responses to vaccine candidates, thereby supporting vaccine development and testing processes. This segment's growth is fueled by increasing investments in vaccine research and development. Regional Analysis: North America dominates the global ELISA testing market, with the United States and Canada leading revenue generation. The region's growth is driven by the demand for timely and accurate diagnosis of infectious and chronic diseases, coupled with the presence of numerous pharmaceutical companies focusing on drug development.For more insights on the market - Download a PDF Sample Report Market Analyst Overview: ELISA testing's versatility in detecting antibodies, biomarkers, and infectious conditions, coupled with cost-effective technologies, is propelling market growth. Automation and advancements in multiplex proteomic array platforms are enhancing testing efficiency and precision. The market is poised for expansion, particularly in cancer diagnostics and immunoassays, driven by increasing health awareness and demand for innovative disease diagnosis tools. Conclusion: In conclusion, the ELISA testing market is set to experience robust growth driven by factors such as the rise in chronic diseases, increasing promotional activities, and advancements in testing technologies. However, challenges related to regulatory compliance remain significant. With key players innovating and expanding their presence, the market is poised for substantial expansion, especially in regions like North America.To learn more about this report - Download a PDF Sample Report Analyst Review Enzyme-Linked Immunosorbent Assay (ELISA) has emerged as a cornerstone technology in the realm of diagnostic testing, particularly in the field of infectious diseases, chronic illnesses, and cancer research. This robust testing method, also known as ELISA assay, utilizes monoclonal antibodies (mABs) to quantify various proteins, including serum antibody concentrations, and detect antigens within biological samples like blood or serum. The worldwide ELISA testing market has witnessed exponential growth driven by the rising prevalence of infectious diseases such as HIV, AIDS, Lyme disease, tuberculosis, meningococcal ailments, and salmonella infections. Additionally, the increasing geriatric populace has propelled the demand for efficient ailment diagnosis tools, further boosting the market value. Continuous technological improvements have enhanced the specificity and efficiency of ELISA tests, paving the way for innovative product offerings such as sandwich ELISA and NS1 ELISA for Zika virus detection. Moreover, advancements like multiple and portable ELISA devices have expanded the market's geographical coverage, reaching previously underserved regions. Key players in the ELISA market, including the Native Antigen Company, have focused on strategic growth initiatives such as product approvals, geographic expansions, and technological innovations to strengthen their market stake and cater to diverse application niches. Regulatory frameworks and public awareness campaigns led by organizations like the World Health Organization (WHO) and the International Society for Infectious Diseases have further facilitated market growth by promoting health awareness and disease diagnosis. The ELISA market's future trajectory looks promising, with a forecasted compound annual growth rate (CAGR) driven by the increasing burden of infectious diseases and the growing adoption of ELISA in cancer applications. Moreover, cost-effective technologies, automation in laboratories, and the emergence of multiplex proteomic array platforms have optimized the value chain and enhanced the cost efficiency of ELISA tests. In conclusion, the enzyme-linked immunosorbent assay (ELISA) market presents lucrative growth opportunities fueled by technological innovations, expanding application domains, and increasing health awareness. With a focus on product advancements, market regulations, and strategic expansions, players in this space are poised to capitalize on emerging revenue pockets and contribute significantly to disease diagnosis and healthcare management globally.To learn more about this report - Download a PDF Sample Report Market Overview The global Enzyme-linked Immunosorbent Assay (ELISA) market continues to expand, driven by advancements in monoclonal antibodies (mABs) and testing methods. ELISA assays are pivotal in drug discovery, aiding in ailment diagnosis and chronic illness management, especially among the geriatric populace. These tests ensure precise protein quantification and serum antibody concentrations, crucial for virus detection and food allergen identification. With evolving ELISA technology enhancing specificity, the market witnesses heightened demand for blood and serum-based assays. As the need for accurate antigen and antibody detection surges worldwide, the ELISA market remains at the forefront, offering reliable solutions for various industries, from healthcare to research and beyond.To learn more about this report - Download a PDF Sample Report Related Reports: Chromatography Market by Technology, End-user, and Geography - Forecast and Analysis 2023-2027: The chromatography market is estimated to grow at a CAGR of 6.82% between 2022 and 2027. The size of the market is forecast to increase by USD 3,785.83 million. The Increasing demand for ion exchange membranes for chromatography in R&D is notably driving the market growth, although factors such as product limitations the market growth. Forensic Technologies Market by Technique, Application, and Geography - Forecast and Analysis 2023-2027: The forensic technologies market is estimated to grow at a CAGR of 11.89% between 2022 and 2027. The size of the market is forecast to increase by USD 6,583.87 million. The increasing crime rate demanding better investigation methods is notably driving the market growth, although factors such as lack of technical know-how or technical professionals may impede the market growth. Table of Contents 1 Executive Summary 2 Landscape 3 Sizing 4 Historic Size 5 Five Forces Analysis 6 Segmentations 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Vendor Landscape 11 Vendor Analysis 12 Appendix About US Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Local Pest Control Company empowers Communities with Knowledge and Solutions to Stay Safe This Summer. OREM, Utah, March 30, 2024 /PRNewswire/ -- Greenix Pest Control, a leader in eco-friendly pest management solutions, is proud to announce its partnership with LymeDisease.org for Lyme Disease Awareness Month this May. In a concerted effort to fight against Lyme disease, Greenix has committed to donating a portion of its profits to support the vital work of LymeDisease.org in educating communities and supporting individuals affected by this tick-borne illness. Lyme Disease is considered the most common vector-borne disease in the U.S., with the Centers for Disease Control and Prevention (CDC) recording that approximately 476,000 Americans are diagnosed and treated for Lyme Disease each year. "We are proud to stand alongside the LymeDisease.org, in their mission to educate communities and support individuals affected by Lyme disease. By dedicating a portion of our profits to this cause, we hope to contribute to increased awareness, prevention, and ultimately, finding a cure for Lyme disease." (Bob Nilsen, CEO of Greenix.) Greenix Pest Control is committed to making an impact by stopping the spread of Lyme Disease in the communities they service. Throughout the month of May, Greenix will donate a portion of proceeds from any new Tick, Flea and Mosquito account sold. The company encourages everyone to be proactive in tick-proofing their homes, surroundings and communities. Proceeds donated in May will support the efforts of LymeDisease.org in helping those affected by Lyme disease. About Greenix Pest Control: Greenix is a leading provider of sustainable pest services, offering innovative solutions to keep homes and businesses pest-free. Their highest commitments are to their community, offering quality products and services that put safety first. Thanks to their dedication to educating and protecting their communities, Greenix continues to be a leader in the industry. For more information about Greenix and its commitment to Lyme Disease Awareness, please visit . Greenix Contact Info: [844-233-7378] SOURCE Greenix Pest Control

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is included in the Food and Drug Administration’s Tropical Disease Priority Review Voucher Program1. The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States. Participants will receive a low, medium or high dose of VLA1601. In addition, the low dose of VLA1601 will be evaluated with an additional adjuvant, either the CpG 1018® adjuvant from Dynavax Technologies Corporation or 3M-052-AF adjuvant from the Access to Advanced Health Institute (AAHI). Topline data from the trial are expected in the first half of 2025. VLA1601 is being developed on the original manufacturing platform of Valneva’s licensed Japanese encephalitis (JE) vaccine IXIARO®, which was further optimized to develop the Company’s inactivated, adjuvanted COVID-19 vaccine VLA2001, the first COVID-19 vaccine to receive a standard marketing authorization in Europe. Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety pro immunogenicity in all tested doses and schedules2. Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, “Valneva’s commitment to our vision – to live in a world in which no one dies or suffers from a vaccine-preventable disease – fuels our pursuit for preparedness solutions against the Zika virus. As global temperatures rise and rainfall increases, the habitat for disease-carrying mosquitoes expands, presenting an ongoing public health challenge.” A vaccine against ZIKV would nicely complement Valneva’s portfolio of travel vaccines against mosquito-borne diseases. The Company received U.S. approval for its chikungunya vaccine IXCHIQ®, the world first and only chikungunya vaccine to address this unmet medical need, in November 2023, and has been commercializing its JE vaccine IXIARO®, for over ten years. Some health authorities and scientific leaders in the field have indicated a preference for a purified inactivated vaccine method compared to other vaccine technologies. This preference stems from the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant. About the Zika Virus The Zika virus (ZIKV) is a mosquito-borne flavivirus that was first discovered in 1947. The first human cases were detected in 1952. Since then, disease outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, in 2015, in the Americas. Zika virus is currently circulating in Mexico, Central and South America, many countries and territories in the Caribbean region, and in a small number of geographically limited areas of the continental United States. To date, a total of 89 countries and territories have reported evidence of mosquito transmitted Zika virus infection; however, surveillance remains limited globally. According to the World Health Organization, there is scientific consensus that ZIKV is a cause of microcephaly and Guillain-Barré syndrome. Since 2013, 31 countries and territories have reported cases of microcephaly and other central nervous system malformations associated with ZIKV infection. About VLA1601 VLA1601 is a highly purified inactivated vaccine candidate against the Zika virus (ZIKV), developed on the original manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine IXIARO®, which was further optimized to develop the Company’s inactivated, adjuvanted COVID-19 vaccine VLA2001, the first COVID-19 vaccine to receive a standard marketing authorization in Europe. Valneva reported positive Phase 1 results for VLA1601 in 20183. The vaccine candidate was immunogenic and showed a favorable safety pro all tested doses and schedules that was comparable to IXIARO® and other clinical stage ZIKV vaccines. About IXIARO®/JESPECT® Valneva’s Japanese encephalitis vaccine is indicated for active immunization for the prevention of the disease for people who travel to, or live in, endemic areas. It received marketing approval in the U.S., Europe, Canada, Hong Kong, Singapore, and Israel under the trade name IXIARO® and in Australia and New Zealand where it is marketed as JESPECT®. It is the only vaccine available to the U.S. military for Japanese Encephalitis. IXIARO® is approved for use in individuals two months of age and older in the U.S. and EU member states, Canada, Norway, Liechtenstein, Iceland, Singapore, Hong Kong, Japan, the Republic of Korea and Israel. In all other licensed territories, IXIARO®/JESPECT® is indicated for use in persons aged 18 years or more. About IXCHIQ® In the U.S., IXCHIQ® is a live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. As for all products approved under FDA’s accelerated approval pathway, continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory studies. Pleaseclick herefor full Prescribing Information for IXCHIQ®. About Valneva SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines as well as certain third-party vaccines leveraging our established commercial infrastructure. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 communications@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com Forward-Looking Statements This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to guidance for certain financial results in fiscal year 2024 and mid-term outlook on financial results, cash position, and other business developments, including results of ongoing clinical trials, the timing and possible occurrence of further or initial regulatory approvals of its product candidates, the anticipated size of markets for its approved products and sales of those products, receipt of funding from external sources, supply of products sold by Valneva, and relationships with current business partners. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. These risks and uncertainties include those developed or identified in any public documents filed with the French financial markets authority (Autorité des marchés financiers) and the U.S. Securities and Exchange Commission made or to be made by Valneva. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines (including in relation to organic or strategic expansion of Valneva’s clinical pipeline), unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis and other global economic or political events, the ability to obtain or maintain patent or other proprietary intellectual property protection, the cancellation of existing contracts, the impact of a pandemic, and changes in the regulatory environment in which Valneva operates. The occurrence of any of these risks and uncertainties could substantially harm Valneva’s business, financial condition, prospects and results of operations. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 Tropical Disease Priority Review Voucher Program | FDA 2 A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine - PubMed (nih.gov) and Emergent Biosolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus - Valneva 3 A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine - PubMed (nih.gov) and Emergent Biosolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus - Valneva Attachment 2024_03_26_VLA1601_Phase1_Initiation_PR_EN_Final